Newer formulations of intravenous iron: a review of their chemistry and key safety aspects–hypersensitivity, hypophosphatemia, and cardiovascular safety

I Blumenstein, S Shanbhag, P Langguth… - Expert opinion on …, 2021 - Taylor & Francis
Introduction: The newest intravenous (IV) iron products show an improved safety profile over
predecessors, allowing for the rapid administration of relatively high doses. Ferric …

High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit-risk assessment

JMM Boots, RAM Quax - Drug safety, 2022 - Springer
The intravenous iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose
(FDI) offer the possibility of administering a large amount of iron in one infusion. This results …

The safety of intravenous iron preparations: systematic review and meta-analysis

T Avni, A Bieber, A Grossman, H Green… - Mayo clinic …, 2015 - Elsevier
Objective To amass all available evidence regarding the safety of intravenous (IV) iron
preparations to provide a true balance of efficacy and safety. Methods Systematic review …

Intravenous irons: from basic science to clinical practice

S Bhandari, DIA Pereira, HF Chappell, H Drakesmith - Pharmaceuticals, 2018 - mdpi.com
Iron is an essential trace mineral necessary for life, and iron deficiency anaemia (IDA) is one
of the most common haematological problems worldwide, affecting a sixth of the global …

[HTML][HTML] Intravenous iron supplementation therapy

B Schaefer, E Meindl, S Wagner, H Tilg… - Molecular aspects of …, 2020 - Elsevier
Intravenous infusions of iron have evolved from a poorly effective and dangerous
intervention to a safe cornerstone in the treatment of iron deficiency. Modern iron …

A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications

MR Jahn, HB Andreasen, S Fütterer, T Nawroth… - European journal of …, 2011 - Elsevier
The treatment of iron deficiency anemia with polynuclear iron formulations is an established
therapy in patients with chronic kidney disease but also in other disease areas like …

[HTML][HTML] Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and …

AP Ambrosy, S von Haehling, PR Kalra, E Court… - The American journal of …, 2021 - Elsevier
Ferric derisomaltose (FDI) is an intravenous (IV) high-dose iron formulation approved in the
US for the treatment of iron deficiency anemia in adults who are intolerant of/have had an …

Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients

A Martin‐Malo, G Borchard, B Flühmann… - ESC heart …, 2019 - Wiley Online Library
Iron deficiency is the leading cause of anaemia and is highly prevalent in patients with
chronic heart failure (CHF). Iron deficiency, with or without anaemia, can be corrected with …

Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease

DW Coyne - Expert opinion on pharmacotherapy, 2009 - Taylor & Francis
Background: Iron deficiency anemia (IDA) is a common problem in patients with chronic
kidney disease (CKD). Use of intravenous (iv) iron effectively treats the resultant anemia, but …

The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose

F Funk, P Ryle, C Canclini, S Neiser… - …, 2010 - thieme-connect.com
An ideal preparation for intravenous iron replacement therapy should balance effectiveness
and safety. Compounds that release iron rapidly tend to cause toxicity, while large …